Skip to content

Deep Track Capital, LP

Follow

13F filer, CIK 1856083, GREENWICH, CT

Deep Track Capital, LP reported $6,138,977,076 across 74 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 44.78% of the portfolio.

Accepted , ingested 13F-HR 0001856083-26-000006

Period
2026-09-30
Reported value
$6.14B
Holdings
74
Top 10 weight
44.78%
New
20
Sold out
13

Part of the filer group Deep Track Capital, LP

  • KROIN DAVID
  • Deep Track Biotechnology Master Fund, Ltd.
  • Deep Track Special Opportunities Fund, LP.
How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • MTRI MENTARI THERAPEUTICS INC: 13G 2,977,478 shares, 5.64% of the class, 13G filed 2026-11-13, 0001172661-26-005030Timeline
    Accepted , ingested
  • TCXB TCGX ACQUISITION CORP II: 13G 990,000 shares, 9.9% of the class, 13G filed 2026-10-23, 0001172661-26-004681Timeline
    Accepted , ingested
  • ALEC ALECTOR INC: 13G 12,772,152 shares, 8.61% of the class, 13G filed 2026-10-23, 0001172661-26-004680Timeline
    Accepted , ingested
  • FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 8.97% of the class, 13G filed 2026-10-21, 0001172661-26-004630Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BMRNadded+3,066,914$184M
INSMnew+1,350,000$154M
VERAadded+3,000,000$96.9M
UTHRadded+176,424$95.6M
LTGOnew+4,408,322$73.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ALNYexited-825,000-$248M
NUVLexited-1,783,322-$220M
IONSexited-2,200,000-$174M
GHreduced-587,635-$105M
GRALreduced-730,744-$102M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001856083-26-000006, largest first. % of portfolio is the value over $5,942,504,076, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GHGUARDANT HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,419,566 shares; 2025Q1: 5,443,721 shares; 2025Q2: 4,250,000 shares; 2025Q3: 4,154,086 shares; 2025Q4: 2,800,000 shares; 2026Q1: 3,338,241 shares; 2026Q2: 3,393,312 shares; 2026Q3: 2,805,677 shares 2,805,677$500M8.42%-587,635Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 24,856 shares; 2025Q4: 2,300,000 shares; 2026Q1: 1,150,000 shares; 2026Q2: 3,307,481 shares; 2026Q3: 6,374,395 shares 6,374,395$382M6.44%+3,066,914Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,000,000 shares; 2025Q1: 9,500,000 shares; 2025Q2: 9,500,000 shares; 2025Q3: 9,728,845 shares; 2025Q4: 11,526,971 shares; 2026Q1: 11,526,971 shares; 2026Q2: 9,341,151 shares; 2026Q3: 9,160,801 shares 9,160,801$309M5.21%-180,350Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 1,484,266 shares; 2025Q2: 1,750,000 shares; 2025Q3: 3,000,000 shares; 2025Q4: 3,004,034 shares; 2026Q1: 3,600,000 shares; 2026Q2: 3,666,768 shares; 2026Q3: 3,806,768 shares 3,806,768$299M5.04%+140,000Timeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 2,000,000 shares; 2026Q3: 1,900,000 shares 1,900,000$230M3.88%-100,000Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,821,135 shares; 2026Q1: 4,106,067 shares; 2026Q2: 4,000,000 shares; 2026Q3: 7,000,000 shares 7,000,000$226M3.8%+3,000,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 750,000 shares; 2025Q2: 2,150,000 shares; 2025Q3: 3,000,000 shares; 2025Q4: 4,000,000 shares; 2026Q1: 4,300,000 shares; 2026Q2: 4,300,000 shares; 2026Q3: 3,513,069 shares 3,513,069$200M3.36%-786,931Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,000,000 shares; 2026Q1: 3,590,323 shares; 2026Q2: 4,000,000 shares; 2026Q3: 4,500,000 shares 4,500,000$182M3.07%+500,000Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 12,836,282 shares; 2025Q1: 14,294,420 shares; 2025Q2: 14,294,420 shares; 2025Q3: 11,932,137 shares; 2025Q4: 8,070,414 shares; 2026Q1: 19,686,282 shares; 2026Q2: 19,686,282 shares; 2026Q3: 21,939,625 shares 21,939,625$168M2.83%+2,253,343Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 123,616 shares; 2026Q3: 300,040 shares 300,040$163M2.74%+176,424Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,800,000 shares; 2025Q1: 4,100,000 shares; 2025Q2: 5,133,917 shares; 2025Q3: 4,215,811 shares; 2025Q4: 4,111,782 shares; 2026Q1: 4,279,848 shares; 2026Q2: 4,740,072 shares; 2026Q3: 5,000,000 shares 5,000,000$156M2.63%+259,928Timeline
GRALGRAIL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,022,797 shares; 2026Q1: 1,722,797 shares; 2026Q2: 1,834,944 shares; 2026Q3: 1,104,200 shares 1,104,200$155M2.6%-730,744Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 254,751 shares; 2025Q2: 1,750,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,350,000 shares 1,350,000$154M2.59%newTimeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 8,859,648 shares; 2025Q2: 8,831,007 shares; 2025Q3: 7,859,648 shares; 2025Q4: 7,334,323 shares; 2026Q1: 12,161,496 shares; 2026Q2: 12,161,496 shares; 2026Q3: 12,161,496 shares 12,161,496$151M2.55%0Timeline
GMABGENMAB A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,000,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 481,267 shares; 2025Q4: not reported; 2026Q1: 3,663,250 shares; 2026Q2: 5,650,000 shares; 2026Q3: 4,182,689 shares 4,182,689$149M2.51%-1,467,311Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 801,371 shares; 2025Q3: 900,000 shares; 2025Q4: 1,150,000 shares; 2026Q1: 1,100,000 shares; 2026Q2: 700,000 shares; 2026Q3: 800,000 shares 800,000$148M2.48%+100,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,000,000 shares; 2025Q1: 5,500,000 shares; 2025Q2: 6,064,910 shares; 2025Q3: 6,057,024 shares; 2025Q4: 7,036,455 shares; 2026Q1: 6,345,244 shares; 2026Q2: 7,736,455 shares; 2026Q3: 6,000,000 shares 6,000,000$142M2.39%-1,736,455Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 3,352,804 shares; 2025Q4: 3,352,804 shares; 2026Q1: 3,352,804 shares; 2026Q2: 3,352,804 shares; 2026Q3: 3,352,804 shares 3,352,804$129M2.17%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,454,562 shares; 2025Q4: 2,454,562 shares; 2026Q1: 2,750,000 shares; 2026Q2: 4,200,000 shares; 2026Q3: 4,500,000 shares 4,500,000$112M1.89%+300,000Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,269,126 shares; 2025Q2: 3,948,910 shares; 2025Q3: 3,948,910 shares; 2025Q4: 4,246,440 shares; 2026Q1: 3,477,562 shares; 2026Q2: 3,732,569 shares; 2026Q3: 4,083,969 shares 4,083,969$111M1.87%+351,400Timeline
COAGHEMAB THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,602,093 shares; 2026Q3: 3,587,796 shares 3,587,796$111M1.86%-14,297Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,610,071 shares; 2026Q1: 6,408,863 shares; 2026Q2: 6,999,025 shares; 2026Q3: 8,105,290 shares 8,105,290$94.8M1.6%+1,106,265Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 750,000 shares; 2025Q1: 1,444,709 shares; 2025Q2: 1,918,798 shares; 2025Q3: 2,654,781 shares; 2025Q4: 2,161,510 shares; 2026Q1: 2,034,203 shares; 2026Q2: 1,926,000 shares; 2026Q3: 1,069,774 shares 1,069,774$89.1M1.5%-856,226Timeline
WGSGENEDX HOLDINGS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 700,000 shares; 2026Q3: 1,200,000 shares 1,200,000$86.8M1.46%+500,0002026-11-10, 13G: 1,800,000 shares, 6.01% of the class, 13G filed 2026-11-17 Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 453,102 shares; 2026Q1: 1,000,000 shares; 2026Q2: 2,000,000 shares; 2026Q3: 2,500,000 shares 2,500,000$80M1.35%+500,000Timeline
GHRSGH RESEARCH PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 2,000,000 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,250,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,333,334 shares; 2026Q3: 3,333,334 shares 3,333,334$78.3M1.32%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,000,000 shares; 2025Q1: 2,000,000 shares; 2025Q2: 2,426,657 shares; 2025Q3: 2,426,657 shares; 2025Q4: 2,614,004 shares; 2026Q1: 4,062,500 shares; 2026Q2: 4,100,000 shares; 2026Q3: 4,100,000 shares 4,100,000$76.3M1.28%0Timeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 4,408,322 shares 4,408,322$73.6M1.24%newTimeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,540,132 shares; 2025Q1: 2,000,000 shares; 2025Q2: 2,000,000 shares; 2025Q3: 2,000,000 shares; 2025Q4: 1,900,738 shares; 2026Q1: 1,283,979 shares; 2026Q2: 2,939,151 shares; 2026Q3: 2,125,532 shares 2,125,532$68.9M1.16%-813,619Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 819,162 shares; 2025Q1: 2,800,000 shares; 2025Q2: 900,000 shares; 2025Q3: 1,200,000 shares; 2025Q4: 810,142 shares; 2026Q1: 841,445 shares; 2026Q2: not reported; 2026Q3: 885,882 shares 885,882$58.3M0.98%newTimeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 867,000 shares; 2025Q1: 859,876 shares; 2025Q2: 567,103 shares; 2025Q3: 144,600 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,610,000 shares; 2026Q3: 3,610,000 shares 3,610,000$55.3M0.93%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 6,772,595 shares; 2026Q2: 6,348,558 shares; 2026Q3: 7,469,746 shares 7,469,746$55.2M0.93%+1,121,188Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 19,250,000 shares; 2026Q3: 19,250,000 shares 19,250,000$55.1M0.93%0Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,207,138 shares 3,207,138$55M0.93%newTimeline
BLLNBILLIONTOONE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 50,000 shares; 2026Q1: 50,000 shares; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$53.2M0.9%newTimeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 9,345,000 shares; 2026Q2: 9,345,000 shares; 2026Q3: 9,345,000 shares 9,345,000$49.2M0.83%0Timeline
CRMDCORMEDIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: 5,274,076 shares; 2026Q1: 6,274,076 shares; 2026Q2: 6,274,076 shares; 2026Q3: 6,274,076 shares 6,274,076$48.3M0.81%0Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 710,421 shares; 2025Q1: 1,400,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,148,817 shares 1,148,817$46.6M0.78%newTimeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 5,740,850 shares; 2026Q1: 5,740,850 shares; 2026Q2: 5,740,850 shares; 2026Q3: 5,740,850 shares 5,740,850$46.2M0.78%0Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,000,000 shares; 2026Q2: 2,750,000 shares; 2026Q3: 1,000,000 shares 1,000,000$38.1M0.64%-1,750,000Timeline
GENBGENERATE BIOMEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,333,815 shares; 2026Q3: 2,507,449 shares 2,507,449$37.7M0.63%+1,173,634Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,018,935 shares; 2025Q1: 3,018,935 shares; 2025Q2: 2,188,592 shares; 2025Q3: 3,150,000 shares; 2025Q4: 3,249,790 shares; 2026Q1: 2,757,569 shares; 2026Q2: 1,732,569 shares; 2026Q3: 640,000 shares 640,000$37.5M0.63%-1,092,569Timeline
ANIPANI PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 649,042 shares; 2025Q1: 700,000 shares; 2025Q2: 700,000 shares; 2025Q3: 450,000 shares; 2025Q4: 477,684 shares; 2026Q1: 600,000 shares; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$36.3M0.61%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,522,741 shares; 2025Q1: 5,380,449 shares; 2025Q2: 5,380,449 shares; 2025Q3: 5,380,449 shares; 2025Q4: 2,524,833 shares; 2026Q1: 1,393,944 shares; 2026Q2: 3,592,740 shares; 2026Q3: 1,711,030 shares 1,711,030$35.2M0.59%-1,881,710Timeline
HROWHARROW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 969,000 shares; 2026Q3: 1,069,000 shares 1,069,000$32.9M0.55%+100,000Timeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,120,050 shares 2,120,050$29.1M0.49%newTimeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,491,539 shares; 2026Q2: 2,491,939 shares; 2026Q3: 2,491,939 shares 2,491,939$28.7M0.48%0Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 200,000 shares 200,000$28.4M0.48%newTimeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,565,062 shares; 2026Q2: 3,565,062 shares; 2026Q3: 3,565,062 shares 3,565,062$25.8M0.43%0Timeline
STTKSHATTUCK LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,706,734 shares; 2026Q3: 3,706,734 shares 3,706,734$25.3M0.43%0Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 315,765 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 820,765 shares; 2026Q2: 1,000,000 shares; 2026Q3: 1,000,000 shares 1,000,000$24.4M0.41%0Timeline
MNKDMANNKIND CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,000,000 shares; 2026Q3: 5,030,522 shares 5,030,522$19.6M0.33%-969,478Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 169,132 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,350,000 shares; 2025Q3: 1,200,000 shares; 2025Q4: 366,435 shares; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$18.6M0.31%newTimeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,442,833 shares; 2025Q1: 3,442,833 shares; 2025Q2: 3,442,833 shares; 2025Q3: 3,470,172 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,500,000 shares; 2026Q3: 2,109,951 shares 2,109,951$18.2M0.31%+609,951Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 300,000 shares; 2026Q3: 300,000 shares 300,000$18.2M0.31%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,323,986 shares 1,323,986$16.6M0.28%newTimeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 9,487,745 shares; 2026Q2: 9,462,645 shares; 2026Q3: 9,462,645 shares 9,462,645$16.2M0.27%0Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 500,000 shares; 2025Q1: 549,439 shares; 2025Q2: 549,439 shares; 2025Q3: 549,439 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 593,551 shares; 2026Q3: 540,000 shares 540,000$13.5M0.23%-53,551Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,318,101 shares 1,318,101$13.4M0.23%newTimeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,956,867 shares; 2026Q1: 1,956,867 shares; 2026Q2: 1,444,167 shares; 2026Q3: 1,000,000 shares 1,000,000$13.2M0.22%-444,167Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,122,484 shares; 2025Q4: 5,013,661 shares; 2026Q1: 6,339,535 shares; 2026Q2: 5,878,757 shares; 2026Q3: 4,501,684 shares 4,501,684$13.1M0.22%-1,377,073Timeline
KARDKARDIGAN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 600,000 shares; 2026Q3: 600,000 shares 600,000$8.85M0.15%0Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 835,655 shares; 2026Q2: 835,655 shares; 2026Q3: 740,117 shares 740,117$8.03M0.14%-95,538Timeline
ENTXENTERA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,450,980 shares 2,450,980$7.13M0.12%newTimeline
RXSTRXSIGHT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,230,566 shares 1,230,566$6.03M0.1%newTimeline
RNAQURAINIER ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$5.1M0.09%newTimeline
JTTTJATT III ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 450,000 shares 450,000$4.96M0.08%newTimeline
RACDRESEARCH ALLIANCE CORP IVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 400,000 shares 400,000$4.63M0.08%newTimeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,000 shares 300,000$3.75M0.06%newTimeline
ALGSALIGOS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 244,110 shares; 2025Q1: 444,110 shares; 2025Q2: 444,110 shares; 2025Q3: 444,110 shares; 2025Q4: 444,110 shares; 2026Q1: 444,110 shares; 2026Q2: 444,110 shares; 2026Q3: 444,110 shares 444,110$2.5M0.04%0Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,419,355 shares; 2025Q1: 7,419,355 shares; 2025Q2: 7,419,355 shares; 2025Q3: 7,419,355 shares; 2025Q4: 7,419,355 shares; 2026Q1: 7,419,355 shares; 2026Q2: 7,419,355 shares; 2026Q3: 7,419,355 shares 7,419,355$2.23M0.04%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
GMABGENMAB A/S Ordinary Shares, nominal value DKK 1 per sharecall2,760,000$98.5M-240,000
TEMTEMPUS AI INC Stockcall1,000,000$81.9Mnew
DYNDYNE THERAPEUTICS INC Stockcall1,000,000$16.1Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ALNYALNYLAM PHARMACEUTICALS INC825,000$248Mshares
NUVLNUVALENT INC1,783,322$220Mshares
IONSIONIS PHARMACEUTICALS INC2,200,000$174Mshares
ATAIATAIBECKLEY INC14,417,442$76Mshares
CYTKCYTOKINETICS INC700,000$59.6Mshares
PSNLPERSONALIS INC4,000,000$53.6Mshares
DYNDYNE THERAPEUTICS INC1,500,000$33.3Mshares
IMMXIMMIX BIOPHARMA INC2,775,000$28.6Mshares
KURAKURA ONCOLOGY INC1,978,565$21.7Mshares
KLRAKAILERA THERAPEUTICS INC700,000$15.4Mshares
ELVNENLIVEN THERAPEUTICS INC225,000$11.4Mshares
IMCRIMMUNOCORE HLDGS PLC311,218$9.88Mshares
IVAINVENTIVA SA800,000$3.02Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001856083-26-000006 base2026-11-16